Nandakumar Selvasudha

Dr. Nandakumar Selvasudha


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SSS. Sowparani
S. Sowparani
PMP. Mahalakshmi
P. Mahalakshmi
JSJ. Pushpa Sweety
J. Pushpa Sweety
AFArul Prakash Francis
Arul Prakash Francis
UDU. M. Dhanalekshmi
U. M. Dhanalekshmi
NSNandakumar Selvasudha
Nandakumar Selvasudha

1 May 2017 in Carbohydrate Polymers
Verified
Journal Article
Closed access
NSNandakumar Selvasudha
Nandakumar Selvasudha
KKKailasam Koumaravelou
Kailasam Koumaravelou

5 September 2019 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
ISIrisappan Sarathchandiran
Irisappan Sarathchandiran
KKKailasam Koumaravelou
Kailasam Koumaravelou
NSNandakumar Selvasudha
Nandakumar Selvasudha
Objective and Methods: This study predicted the nature of chitosan interactions and effects of this interaction on drug release mechanism in simvastatin loaded chitosan nanoformulation using molecular docking, spectroscopic and thermal analysis. Significance: This work explains in depth the molecular mechanism of simvastatin and chitosan bond formation in nanoformulation. Results: The effective encapsulation and sustain release properties of chitosan was indicated by increase in melting endotherm of simvastatin. Intermolecular hydrogen bond between third hydroxyl group pyranone ring of simvastatin and amino group of chitosan represented the stability of active lactone moiety that was not cleaved during formulation which is prerequisite for biological activity. UV-Vis spectroscopic characterization, shift in infrared vibration wavenumber of simvastatin and chitosan, ligand titration and 1HNMR, 13C-NMR analysis confirmed this interaction pattern. The pharmacokinetic evaluation in mouse model revealed the sustain release property of nanoformulation. Conclusion: Thus formation of intermolecular hydrogen bond in nanoformulation contributed modified physicochemical properties and improved in vivo performance of simvastatin.

24 February 2021
Verified
Book Chapter
Open access
PDF file
NSNandakumar Selvasudha
Nandakumar Selvasudha
UDUnnikrishnan-Meenakshi Dhanalekshmi
Unnikrishnan-Meenakshi Dhanalekshmi
SKSekar Krishnaraj
Sekar Krishnaraj
YSYogeeswarakannan Harish Sundar
Yogeeswarakannan Harish Sundar
NDNagarajan Sri Durga Devi
Nagarajan Sri Durga Devi
ISIrisappan Sarathchandiran
Irisappan Sarathchandiran
Clay has its widespread applications in pharmaceuticals from ancient world to modern era. It is one of the excellent excipients present in the commercially available pharmaceuticals. Its use in many of dosage forms viz. in suspension, emulsion, ointments, gels, tablet and as drug delivery carrier as suspending agent, emulsifying agent, stiffening agent, binder, diluent, opacifier, and as release retardant have been explored in many studies. Variety of minerals is used as both excipient and as an active ingredient; among that kaolinite, talc, and gypsum are important. Their inertness, low toxicity, versatile physiochemical properties and cost effectiveness has increased its usage in pharma industries. Many minerals have its own pharmacological action as antacid, anti-bacterial, anti-emetic, anti- diarrheal agent and as skin protectant etc. Their unique structure which helps them to absorb material onto their layered sheets has opened a wide variety of applications in drug delivery. The understanding of surface chemistry and particle size distribution of clay minerals has led the pharmaceutical field in many directions and future perspectives.

10 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AFArul Prakash Francis
Arul Prakash Francis
Aftab AhmadAftab Ahmad
Aftab Ahmad
DNDurga Nagarajan
Durga Nagarajan
HYHarish Sundar Yogeeswarakannan
Harish Sundar Yogeeswarakannan
KSKrishnaraj Sekar
Krishnaraj Sekar
NSNandakumar Selvasudha
Nandakumar Selvasudha
Acyclovir (ACV) is a promising candidate for drug repurposing because of its potential to provide an effective treatment for viral infections and non-viral diseases, such as cancer, for which limited treatment options exist. However, its poor physicochemical properties limit its application. This study aimed to formulate and evaluate an ACV-loaded red clay nanodrug delivery system exhibiting an effective cytotoxicity. The study focused on the preparation of a complex between ACV and red clay (RC) using sucrose stearate (SS) (nanocomplex F1) as an immediate-release drug-delivery system for melanoma treatment. The synthesized nanocomplex, which had nanosized dimensions, a negative zeta potential and the drug release of approximately 85% after 3 h, was found to be promising. Characterization techniques, including FT-IR, XRD and DSC-TGA, confirmed the effective encapsulation of ACV within the nanocomplex and its stability due to intercalation. Cytotoxicity experiments conducted on melanoma cancer cell lines SK-MEL-3 revealed that the ACV release from the nanocomplex formulation F1 effectively inhibited the growth of melanoma cancer cells, with an IC50 of 25 ± 0.09 µg/mL. Additionally, ACV demonstrated a significant cytotoxicity at approximately 20 µg/mL in the melanoma cancer cell line, indicating its potential repurposing for skin cancer treatment. Based on these findings, it can be suggested that the RC-SS complex could be an effective drug delivery carrier for localized cancer therapy. Furthermore, the results of an in silico study suggested the addition of chitosan to the formulation for a more effective drug delivery. Energy and interaction analyses using various modules in a material studio demonstrated the high stability of the composite comprising red clay, sucrose stearate, chitosan and ACV. Thus, it could be concluded that the utilization of the red clay-based drug delivery system is a promising strategy to improve the effectiveness of targeted cancer therapy.

1 June 2022 in Drug Metabolism Letters
Verified
Journal Article
Closed access
PDF file
AAAlka Ahuja
Alka Ahuja
DMDhanalekshmi Unnikrishnan Meenakshi
Dhanalekshmi Unnikrishnan Meenakshi
SMSaraswathy Mp
Saraswathy Mp
NSNandakumar Selvasudha
Nandakumar Selvasudha
AFArul Prakash Francis
Arul Prakash Francis
GKGurpreet Kn
Gurpreet Kn
Metabolic diseases including cardiovascular diseases (CVD) and diabetes have evolved as the leading cause of morbidity and mortality worldwide. Gut microbiota appears to play a vital role in human disease and health, according to recent scientific reports. The gut microbiota plays an important role in sustaining host physiology and homeostasis by creating a cross-talk between the host and microbiome via metabolites obtained from the host's diet. Drug developers and clinicians rely heavily on therapies that target the microbiota in the management of metabolic diseases and the gut microbiota is considered the biggest immune organ in the human body. They are highly associated with intestinal immunity and systemic metabolic disorders like CVD and diabetes and are reflected as potential therapeutic targets for the management of metabolic diseases. This review discusses the mechanism and interrelation between the gut microbiome and metabolic disorders. It also highlights the role of the gut microbiome and microbially derived metabolites in the pathophysiological effects related to CVD and diabetes. It also spotlights the reasons that lead to alterations of microbiota composition and prominence of gut microbiota restoration and targeting approaches as effective treatment strategies in diabetes and CVD. Future research should focus on the understanding of the functional level of some specific microbial pathways that helps to maintain physiological homeostasis, multi-omics, and also in the development of novel therapeutic strategies that intervene with the gut microbiome for the prevention of CVD and diabetes that contribute to a patient's well-being.